Integrated Biopharma Cash Flow - Quarterly (OTCMKTS:INBP)

Add to My Stocks
$0.16 $0 (0%) INBP stock closing price Sep 21, 2018 (Closing)

For analyzing any company like Integrated Biopharma from an investment perspective, its important to check the cash flow statement. The profit-loss statement shows Integrated Biopharma profits, the balance sheet shows Integrated Biopharma debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Integrated Biopharma stock analysis shows negative net income cash flow of $- till 2018 Q4. This statement is important because profits alone cannot pay employees, or bills. Cash is required. Integrated Biopharma has a negative cash and cash equivalents change of $-.

View and download details of Integrated Biopharma cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jul - Jun2018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q3
Net Income Cash Flow
--0.13M-0.52M-0.17M2.34M-----
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities---1.5M-2.13M-0.64M-1.03M-1.67M-2.2M-1.6M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net-----0.2M----0.1M-
Net Cash from (used by) Operating Activities
1.17M1.34M-1.6M-1.21M--0.52M-0.59M-0.81M
Increase (Decrease) in Prop Plant And Equipment-0.24M-0.21M-0.2M-0.1M-0.32M-0.31M-0.08M-0.04M-0.1M-0.03M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
-0.24M-0.21M-0.2M-0.1M-0.32M-0.31M-0.08M-0.04M-0.1M-0.03M
Issuance (Purchase) of Equity Shares----------
Issuance (Repayment) of Debt Securities-0.23M-0.98M-0.76M-0.57M-0.96M-0.76M-0.58M-0.41M1.27M1.48M
Increase (Decrease) in Bank & Other Borrowings-0.74M-0.35M--0.77M--0.5M-0.2M--0.25M-0.24M
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
-0.83M-1.2M-0.51M-1.34M-0.33M-1.1M-0.79M-1.02M1.23M
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
--0.07M-0.07M--0.26M-0.19M-0.32M-0.3M--
Cash & Equivalents at Beginning of Year----------
Cash & Equivalents at Year End----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Integrated Biopharma stock price history and Integrated Biopharma stock comparison chart inevitably reflect its cash flow situation.

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Integrated Biopharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Integrated Biopharma stock price movement.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a positive value of $1.17M for INBP.
  • Cash Flow from investment activities: Integrated Biopharma used $-0.24M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $-0.83M for Integrated Biopharma.

Key Financial Ratios For Integrated Biopharma Cash Flow

Quarterly Cash Flow Statements For Integrated BioPharma, Inc. Peers

Aceto cash flow, Boston Therapeutics cash flow, Cambrex cash flow, Bio Blast Pharma cash flow, SurModics cash flow